Sign in
Safety and Efficacy of SC Elamipretide to Treat Noncentral Geographic Atrophy: ReCLAIM-1 Results and Phase II ReCLAIM-2 Baseline Characteristics
David R Lally, MD
Annual Meeting Talks
2021
Intravitreal Gene Therapy for Neovascular AMD With ADVM-022: Results of the Phase 1 OPTIC Trial
Charles C Wykoff, MD, PhD, FASRS
Updates from the Field
2020
Relationship Between Number of Intermediate-Large Drusen and Geographic Atrophy Lesion Growth Rate in the Sham Groups of the DERBY, OAKS, and FILLY Trials
Eleonora Lad, MD, PhD
2022
Category: AMD-Neovascular